[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"deep-venous-thromboses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:deep-venous-thromboses":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100611630","phase-4-comparative-efficacy-of-rivaroxaban-and-enoxaparin-in-post-laparotomy-dvt-prevention-100611630",false,"NCT07243080","Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","Comparison Between the Efficacy of Rivaroxaban vs Enoxaparin in Post-Operative Deep Venous Thrombosis Prophylaxis After Exploratory Laparotomy","Inclusion Criteria:• Patients aged 18 to 80 years\n\n* Both male or female patients\n* Patients who have undergone emergent exploratory laparotomy for any reason whether traumatic or non-traumatic\n* Patients with expected immobility for more than 24 hours\n\nExclusion Criteria:\n\n* Patients with diagnosed pre-operative DVT\n* BMI more than 40\n* Patient who are on mechanical ventilation post operatively\n* Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident\n* Patients who have undergone limb surgery in addition to exploratory laparotomy","ALL","18 Years","80 Years",{"count":20,"type":21},212,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults. It will also learn about the safety of rivaroxaban compared to enoxaparin.\n\nThe main questions it aims to answer are:\n\nDoes rivaroxaban lower the number of patients who develop DVT after exploratory laparotomy compared to enoxaparin?\n\nWhat medical problems or side effects do participants have when taking rivaroxaban versus enoxaparin?\n\nResearchers will compare rivaroxaban (an oral anticoagulant) to enoxaparin (a subcutaneous injection) to see which drug works better to prevent blood clots after surgery.\n\nParticipants will:\n\nTake rivaroxaban 10 mg orally once daily for 7 days, or enoxaparin 40 mg subcutaneously once daily for 7 days after surgery\n\nUndergo duplex color Doppler ultrasound scans of the legs on day 5 and day 10 after surgery\n\nBe monitored for bleeding, complications, and other side effects",[27,28],"Deep Venous Thromboses","Laparotomy Patients",[30,31,32,33,34,35,36,37,38],"Deep Vein Thrombosis","Exploratory Laparotomy","Rivaroxaban","Enoxaparin","Venous Thromboembolism","Anticoagulation","Prophylaxis","Randomized Controlled Trial","Thromboprophylaxis","RECRUITING","2025-11-19",{"date":42,"type":43},"2025-11-21","ACTUAL",{"date":45,"type":43},"2025-10-10",{"date":47,"type":21},"2025-11-15",{"name":49,"class":50},"Mayo Hospital Lahore","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":5},"100587231","phase-3-immunosuppressive-therapy-alone-versus-plus-oral-anticoagulation-in-the-treatment-of-vt-associated-with-behcets-disease-100587231","NCT06925698","Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","Immunosuppressive Therapy Alone Versus Immunosuppressive Therapy Plus Oral Anticoagulation in the Treatment of Lower Extremity Venous Thrombosis Associated With Behcet's Disease","BETTER","Inclusion Criteria:\n\n* Participants must meet the following criteria to be eligible for the study:\n\nAge between 18-50 years old. Diagnosed with Behçet's Disease according to the International Study Group (ISG) criteria.\n\nNo prior vascular involvement or no previous immunosuppressive therapy for vascular involvement.\n\nConfirmed venous thrombosis in the lower extremity within the last 14 days before randomization.\n\nVenous thrombosis diagnosis confirmed by:\n\nNon-compressible venous segment in ultrasound, OR A significant (\\>4 mm) increase in thrombus diameter in an already abnormal segment, OR New intraluminal filling defect on venography, CT, or MR angiography.\n\nFemale participants must:\n\nNot be pregnant or breastfeeding. Use effective contraception if of childbearing potential. Be postmenopausal (no menses for at least 1 year) or have undergone surgical sterilization.\n\nAbility to provide written informed consent and comply with study requirements.\n\nExclusion Criteria:\n\n* Participants will be excluded if they meet any of the following criteria:\n\nPresence of any aneurysm. Chronic multisystemic disease other than Behçet's Disease. History of intolerance to Rivaroxaban. Use of immunosuppressive drugs (azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, TNF inhibitors, or interferon-gamma) within the last 6 months.\n\nProlonged corticosteroid use (\\>3 months) for Behçet's Disease mucocutaneous symptoms.\n\nPrior anticoagulant therapy:\n\nLow molecular weight heparin, fondaparinux, or unfractionated heparin for \\>48 hours before randomization.\n\nMore than one dose of vitamin K antagonists before randomization. Thrombectomy, vena cava filter placement, or fibrinolytic therapy for the current thrombotic episode.\n\nPlanned administration of a live vaccine within 30 days after randomization. Clinically significant acute or uncontrolled chronic diseases (e.g., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, or infectious diseases) that may interfere with study results.\n\nPlanned surgical procedure or significant medical condition deemed unsuitable for the study by the investigator.\n\nHistory of malignancy within the last 5 years (except adequately treated basal or squamous cell carcinoma or carcinoma in situ of the cervix).\n\nRenal impairment (Creatinine clearance \\\u003C30 ml\u002Fmin). Severe liver disease (e.g., acute hepatitis, active chronic hepatitis, cirrhosis, or ALT \\>3 times the upper limit).\n\nActive bleeding or high bleeding risk contraindicating anticoagulant therapy. Uncontrolled hypertension (SBP \\>180 mmHg or DBP \\>110 mmHg). Severe anemia (Hemoglobin \\\u003C10 mg\u002FdL). Women who are pregnant, breastfeeding, or of childbearing potential without contraception.\n\nUse of strong CYP3A4 inhibitors or inducers (e.g., protease inhibitors, systemic ketoconazole, rifampin, carbamazepine, phenytoin).\n\nParticipation in another experimental drug study within the last 30 days. Life expectancy of less than 3 months. History of serious infections within the last 60 days (e.g., bacterial endocarditis, tuberculosis, opportunistic infections).\n\nActive substance or alcohol abuse or history of substance dependence within the last year.\n\nPositive screening for Hepatitis B surface antigen, Hepatitis C antibody, or known HIV-1 infection.\n\nKnown coagulation disorders or laboratory abnormalities (e.g., DMID toxicity scale Grade 3 or higher).\n\nHistory of suicidal behavior in the last 6 months or suicidal ideation (C-SSRS type 4 or 5) in the last 2 months.","50 Years",{"count":62,"type":21},110,[64],"PHASE3","This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).",[67,68,27,69],"Behcet Disease","Behcet Disease and Vascular Involvement","Post Thrombotic Syndrome",[71,72,73,32],"Behcet's disease","Deep venous thrombosis","Anticoagulant therapy","NOT_YET_RECRUITING","2025-04-07",{"date":77,"type":43},"2025-04-13",{"date":79,"type":21},"2025-04-30",{"date":81,"type":21},"2028-04-01",{"name":83,"class":50},"Marmara University"]